Necrotizing enterocolitis (NEC) is a serious gastrointestinal condition affecting predominantly premature infants. Per its definition, the intestinal wall is invaded by bacteria, triggering local infection and inflammation that can destroy bowel wall tissue. Bowel wall destruction may result in intestinal perforation, spillage of intestinal contents into the abdominal cavity, and life-threatening systemic infection. A recognized subtype, perinatal necrotizing enterocolitis, is catalogued in structured disease ontologies.

Phenotype data is not included in the current structured packet for necrotizing enterocolitis. Per the condition's definition, the disease involves bacterial invasion of the intestinal wall with progressive inflammation and tissue destruction. The extent of bowel involvement and associated systemic effects vary among affected infants.

Necrotizing enterocolitis arises through bacterial invasion of the intestinal wall, occurring predominantly in premature infants as described in the condition's definition. No germline genetic variants appear in the structured knowledge packet, consistent with an acquired, multifactorial etiology in which prematurity is the predominant risk context.

Structured diagnostic criteria are not included in the knowledge packet for necrotizing enterocolitis. Diagnostic evaluation in clinical practice reflects the evolving evidence base and varies by clinical setting, gestational age, and the severity of bowel involvement.

No FDA-approved treatments are listed in the structured knowledge packet for necrotizing enterocolitis. All orphan drug designations associated with this condition represent agents under investigation or in development, not approved therapies. Clinical management addresses acute intestinal injury and systemic complications through approaches adapted to each infant's clinical status.

Prognosis information is not included in the structured knowledge packet. Per the condition definition, necrotizing enterocolitis can result in life-threatening systemic infection in premature infants, with outcomes varying depending on the extent of bowel involvement and associated complications.

Necrotizing enterocolitis is an active area of clinical research. Per structured data, more than 200 published studies have been classified for this condition, with a substantial proportion of reviews and meta-analyses. Numerous clinical trials are investigating prevention and treatment approaches spanning microbiome-based interventions, biologics, and supportive strategies. Current trial listings are available through ClinicalTrials.gov.